%0 Journal Article %A Daniel B. Larremore %A Bryan Wilder %A Evan Lester %A Soraya Shehata %A James M. Burke %A James A. Hay %A Milind Tambe %A Michael J. Mina %A Roy Parker %T Surveillance testing of SARS-CoV-2 %D 2020 %R 10.1101/2020.06.22.20136309 %J medRxiv %P 2020.06.22.20136309 %X The COVID-19 pandemic has created a public health crisis. Because SARS-CoV-2 can spread from individuals with pre-symptomatic, symptomatic, and asymptomatic infections [1, 2, 3], the re-opening of societies and the control of virus spread will be facilitated by robust surveillance, for which virus testing will often be central. After infection, individuals undergo a period of incubation during which viral titers are usually too low to detect, followed by an exponential growth of virus, leading to a peak viral load and infectiousness, and ending with declining viral levels and clearance [4]. Given the pattern of viral load kinetics [4], we model surveillance effectiveness considering test sensitivities, frequency, and sample-to-answer reporting time. These results demonstrate that effective surveillance, including time to first detection and outbreak control, depends largely on frequency of testing and the speed of reporting, and is only marginally improved by high test sensitivity. We therefore conclude that surveillance should prioritize accessibility, frequency, and sample-to-answer time; analytical limits of detection should be secondary.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors wish to thank the BioFrontiers Institute IT HPC group. This work was supported by grants NIH F32 AI145112 (James Burke), NIH F30 AG063468 (Evan Lester), MURI W911NF-17-1-0370 (Milind Tambe), an NIH directors DP5 award 1DP5OD028145-01 (Michael Mina), and the Howard Hughes Medial Institute (Roy Parker).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB approval was not necessary for this modeling study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSimulation code is available via GitHub. https://github.com/LarremoreLab/covid_surveillance_testing %U https://www.medrxiv.org/content/medrxiv/early/2020/06/25/2020.06.22.20136309.full.pdf